Myriad Genetics (MYGN) Misses Q4 EPS by 1c; Guides Below the Street

Myriad Genetics (NASDAQ: MYGN) reported Q4 EPS of $0.41, $0.01 worse than the analyst estimate of $0.42. Revenue for the quarter came in at $189.9 million versus the consensus estimate of $187.77 million.

Myriad Genetics sees FY2016 EPS of $1.60-$1.65, versus the consensus of $1.75. Myriad Genetics sees FY2016 revenue of $750-770 million, versus the consensus of $760.07 million.

Myriad Genetics sees Q1 2016 EPS of $0.34-$0.36, versus the consensus of $0.40. Myriad Genetics sees Q1 2016 revenue of $176-178 million, versus the consensus of $185.1 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Cerebras Q1 EPS miss sends shares down 9% after-hours